, Volume 71, Issue 11, pp 1413–1439

Difficult-to-Treat Gouty Arthritis

A Disease Warranting Better Management
Review Article


Gouty arthritis is the most common inflammatory arthritis in adults and is characterized by very painful flares. Gouty arthritis results from an elevated body uric acid pool, which leads to deposition of monosodium urate crystals, mainly in the joints. These crystals trigger the release of proinflammatory cytokines, in particular interleukin (IL)-1β, which stimulates inflammation. Gouty arthritis can progress to a chronic, deforming and physically disabling disease through the development of disfiguring tophi, joint destruction and persistent pain. Standard treatments are effective in most patients. Acutely, anti-inflammatory therapies provide rapid pain relief and resolution of flares. Chronically, urate-lowering therapies reduce serum urate levels and, in combination with anti-inflammatory prophylaxis, reduce the risk of flares. However, for a growing number of patients, current standard treatments are ineffective or are contraindicated, largely due to the presence of co-morbidities. Indeed, metabolic syndrome, hypertension, dyslipidaemia, cardiovascular disease, diabetes mellitus and renal impairment are all highly prevalent in individuals with gouty arthritis, and may lead to standard treatments being ineffective or inappropriate. Such patients with difficult-to-treat disease require alternative therapies.

Gouty arthritis can have a major impact on health-related quality of life (HR-QOL), especially in patients with difficult-to-treat disease, as revealed by recent studies comparing HR-QOL for patients with gouty arthritis with that of the general population. All studies revealed clinically significant reductions in physical functioning for individuals with gouty arthritis compared with the general population. The difference was particularly marked for patients with difficult-to-treat disease. Gouty arthritis also constitutes an important economic burden through absence from work and medical costs. Again, the burden is greater in patients with difficult-to-treat disease.

The development of difficult-to-treat disease reflects the short-comings of current standard treatments in a growing number of gouty arthritis patients. This has been recognized by the pharmaceutical industry and has promoted the development of innovative therapies. An appreciation of the key role of IL-1b in inflammation in gouty arthritis has led to the development of a new class of anti-inflammatory agents that block IL-1β signal transduction. The current IL-1β blockers in trials are rilonacept and canakinumab. Canakinumab, a fully human anti-IL-1β monoclonal antibody, has been shown to produce rapid and sustained pain relief from acute flares in patients with difficult-to-treat disease, and both rilonacept and canakinumab have been shown to reduce the risk of recurrent flares. Promising new therapies for reducing serum urate levels are also being developed. These include the recently approved therapies pegloticase (a pegylated form of the enzyme uricase that converts urate to allantoin), inhibitors of renal urate transporter proteins, and inhibitors of purine nucleotide phosphorylase, an enzyme involved in purine metabolism. Further studies are warranted to establish the value and role of these new therapies in the management of gouty arthritis. These new options should help reduce the growing human burden associated with gouty arthritis, lowering the tophaceous burden, minimizing the risk of flares, and enabling patients to achieve rapid and effective pain relief when flares do occur.


  1. 1.
    Schlesinger N. Diagnosis of gout. Minerva Med 2007; 98(6): 759–67PubMedGoogle Scholar
  2. 2.
    Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 2005; 11 Suppl. 15: 443–50; quiz 465-8Google Scholar
  3. 3.
    Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 2008; 75 Suppl. 5: 5–8CrossRefGoogle Scholar
  4. 4.
    Dalbeth N, Clark B, Gregory K, et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 2009; 68(8): 1290–5PubMedCrossRefGoogle Scholar
  5. 5.
    Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010; 69(11): 1907–12PubMedCrossRefGoogle Scholar
  6. 6.
    Zhu Y, Pandya B, Choi H. Increasing gout prevalence in the US over the last two decades: the national health and nutrition examination survey (NHANES). 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7–11; Atlanta (GA)Google Scholar
  7. 7.
    Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 2002; 40(1): 37–42PubMedCrossRefGoogle Scholar
  8. 8.
    Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31(8): 1582–7PubMedGoogle Scholar
  9. 9.
    Zeng Q, Wang Q, Chen R, et al. Primary gout in Shantou: a clinical and epidemiological study. Chin Med J (Engl) 2003; 116(1): 66–9Google Scholar
  10. 10.
    Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995; 48(9): 1153–8PubMedCrossRefGoogle Scholar
  11. 11.
    Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004; 50(8): 2400–14PubMedCrossRefGoogle Scholar
  12. 12.
    Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10(6): 308–14PubMedCrossRefGoogle Scholar
  13. 13.
    Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81(7): 925–34PubMedCrossRefGoogle Scholar
  14. 14.
    Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008; 14(2): 164–75PubMedGoogle Scholar
  15. 15.
    Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11(2): R46PubMedCrossRefGoogle Scholar
  16. 16.
    Halpern R, Mody RR, Fuldeore MJ, et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009; 25(7): 1711–9PubMedCrossRefGoogle Scholar
  17. 17.
    Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009; 48(5): 582–6CrossRefGoogle Scholar
  18. 18.
    Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 2005; 64(2): 267–72PubMedCrossRefGoogle Scholar
  19. 19.
    Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 2007; 46(9): 1441–4CrossRefGoogle Scholar
  20. 20.
    Roddy E, Mallen CD, Hider SL, et al. Prescription and co-morbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 2010; 49(1): 105–11CrossRefGoogle Scholar
  21. 21.
    Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008; 67(7): 960–6PubMedCrossRefGoogle Scholar
  22. 22.
    Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Severity of gout and mortality [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1946Google Scholar
  23. 23.
    Koh WH, Seah A, Chai P. Clinical presentation and disease associations of gout: a hospital-based study of 100 patients in Singapore. Ann Acad Med Singapore 1998; 27(1): 7–10PubMedGoogle Scholar
  24. 24.
    Yood RA, Baraf HSB, Becker MA, et al. Clinical manifestations of treatment failure gout (TFG) in four independent cohorts [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 323Google Scholar
  25. 25.
    Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009; 36(5): 1041–8PubMedCrossRefGoogle Scholar
  26. 26.
    Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 1997; 50(8): 953–9PubMedCrossRefGoogle Scholar
  27. 27.
    Scott JT, Higgens CS. Diuretic induced gout: a multi-factorial condition. Ann Rheum Dis 1992; 51(2): 259–61PubMedCrossRefGoogle Scholar
  28. 28.
    Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57(1): 109–15PubMedCrossRefGoogle Scholar
  29. 29.
    Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005; 20(6): 1029–33PubMedCrossRefGoogle Scholar
  30. 30.
    Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19(12): 2407–13PubMedCrossRefGoogle Scholar
  31. 31.
    Rocca Rey LA. Prevalence and costs of gout in patients with chronic kidney disease in a privately insured population [abstract]. Arthritis Rheum 2007; 56 Suppl. 9: 89Google Scholar
  32. 32.
    Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008; 67(9): 1310–6PubMedCrossRefGoogle Scholar
  33. 33.
    Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004; 63(6): 723–9PubMedCrossRefGoogle Scholar
  34. 34.
    Khanna D, Ahmed M, Yontz D, et al. The disutility of chronic gout. Qual Life Res 2008; 17(5): 815–22PubMedCrossRefGoogle Scholar
  35. 35.
    Khanna P, Perex-Ruiz F, Maranian P, et al. Urate-lowering therapy results in clinically important improvements in health-related quality of life-analysis from an academic clinical practice [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3:717CrossRefGoogle Scholar
  36. 36.
    Strand V, Edwards L, Singh JA. Health-related quality-of-life (HRQOL) of patients with treatment failure gout (TFG) is poor, and comparable to that in other severe chronic conditions [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 168Google Scholar
  37. 37.
    Strand V, Edwards NL, Baraf HSB, et al. Improvement in health-related quality of life (HRQOL) in patients with treatment failure gout (TFG) treated with pegloticase measured by SF-6D derived utility [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1101Google Scholar
  38. 38.
    Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 2011; 13(2):R53PubMedCrossRefGoogle Scholar
  39. 39.
    Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007; 13 Suppl. 9: 237–51Google Scholar
  40. 40.
    Strand V, Petri M, Buyon J, et al. Systemic lupus erythematosus (SLE) impacts all domains of health-related quality of life (HRQOL): baseline results from five randomized controlled trials (RCTs) [abstract]. Ann Rheum Dis 2007; 66 Suppl. 2: 482Google Scholar
  41. 41.
    Martin M, Blaisdell-Gross B, Fortin EW, et al. Health-related quality of life of heart failure and coronary artery disease patients improved during participation in disease management programs: a longitudinal observational study. Dis Manag 2007; 10(3): 164–78PubMedCrossRefGoogle Scholar
  42. 42.
    Piotrowicz K, Noyes K, Lyness JM, et al. Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II. Eur Heart J 2007; 28(5): 601–7PubMedCrossRefGoogle Scholar
  43. 43.
    Alvarez-Hernandez E, Pelaez-Ballestas I, Vazquez-Mellado J, et al. Validation of the Health Assessment Questionnaire disability index in patients with gout. Arthritis Rheum 2008; 59(5): 665–9PubMedCrossRefGoogle Scholar
  44. 44.
    Alvarez-Nemegyei J, Cen-Piste JC, Medina-Escobedo M, et al. Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout. J Rheumatol 2005; 32(10): 1923–7PubMedGoogle Scholar
  45. 45.
    So A, De Meulemeester M, Pikhlak A, et al. Rapid improvement in health-related quality of life (HRQoL) in gouty arthritis patients treated with canakinumab (ACZ885) compared to triamcinolone acetonide. 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7–11; Atlanta (GA)Google Scholar
  46. 46.
    Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health 2007; 10(4): 231–7PubMedCrossRefGoogle Scholar
  47. 47.
    Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum 2008; 58(9): 2587–90PubMedCrossRefGoogle Scholar
  48. 48.
    Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006; 22(7): 1381–9PubMedCrossRefGoogle Scholar
  49. 49.
    Hanly JG, Skedgel C, Sketris I, et al. Gout in the elderly: a population health study. J Rheumatol 2009; 36(4): 822–30PubMedCrossRefGoogle Scholar
  50. 50.
    Wu EQ, Yu AP, Guerin A, et al. The costs of treatment failure gout: a claims-based analysis [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1112Google Scholar
  51. 51.
    Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009; 36(5): 1032–40PubMedCrossRefGoogle Scholar
  52. 52.
    Halpern R, Fuldeore MJ, Mody RR, et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009; 15(1): 3–7PubMedCrossRefGoogle Scholar
  53. 53.
    Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout: part II, management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65(10): 1312–24PubMedCrossRefGoogle Scholar
  54. 54.
    Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51(3): 321–5PubMedCrossRefGoogle Scholar
  55. 55.
    Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13–8PubMedCrossRefGoogle Scholar
  56. 56.
    Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64(21): 2399–416PubMedCrossRefGoogle Scholar
  57. 57.
    Schlesinger N, Moore DF, Sun JD, et al. A survey of current evaluation and treatment of gout. J Rheumatol 2006; 33(10): 2050–2PubMedGoogle Scholar
  58. 58.
    Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 2007; 34(7): 1566–8PubMedGoogle Scholar
  59. 59.
    Gnanenthiran SR, Hassett GM, Gibson KA, et al. Acute gout management during hospitalisation: a need for a protocol. Intern Med J. Epub 2010 Jan 4Google Scholar
  60. 60.
    Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50(2): 598–606PubMedCrossRefGoogle Scholar
  61. 61.
    Schumacher Jr HR, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324(7352): 1488–92PubMedCrossRefGoogle Scholar
  62. 62.
    Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007; 19(2): 122–7PubMedCrossRefGoogle Scholar
  63. 63.
    Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347(26): 2104–10PubMedCrossRefGoogle Scholar
  64. 64.
    American Geriatric Society. Panel on the pharmacological mangement of persistent pain in older persons. J Am Geriatr Soci 2009; 57: 1331–46CrossRefGoogle Scholar
  65. 65.
    Hoskison KT, Wortmann RL. Management of gout in older adults: barriers to optimal control. Drugs Aging 2007; 24(1): 21–36PubMedCrossRefGoogle Scholar
  66. 66.
    Kelly W, Wortmann RL. Crystal-associated synovitis: gout and hyperuricemia. Philadelphia (PA): Saunders, 1993Google Scholar
  67. 67.
    Katzung BG. Nonsteroidal anti-inflammatory drugs; nonopioid analgesics; drugs used in gout. In: Katzung BG, editor. Basic and clinical pharmacology. Norwalk: Apleton and Lange, 1995: 536–59Google Scholar
  68. 68.
    Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440(7081): 237–41PubMedCrossRefGoogle Scholar
  69. 69.
    Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind,placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62(4): 1060–8PubMedCrossRefGoogle Scholar
  70. 70.
    Colcrys® (Colchicine) [package insert]. Philadelphia (PA): AR Scientific Inc, 2009Google Scholar
  71. 71.
    Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31(12): 2429–32PubMedGoogle Scholar
  72. 72.
    Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout: a placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974; 17(5): 609–14PubMedCrossRefGoogle Scholar
  73. 73.
    Janssens HJ, Lucassen PL, Van de Laar FA, et al. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008; (2): CD005521Google Scholar
  74. 74.
    Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371(9627): 1854–60PubMedCrossRefGoogle Scholar
  75. 75.
    Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20(1): 111–3PubMedGoogle Scholar
  76. 76.
    Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994; 21(7): 1325–7PubMedGoogle Scholar
  77. 77.
    So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for treatment of acute flares in refractory gouty arthritis. Arthritis Rheum 2010; 62(10): 3064–74PubMedCrossRefGoogle Scholar
  78. 78.
    Fernandez C, Noguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26(10): 2285–6PubMedGoogle Scholar
  79. 79.
    Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009; 48 Suppl. 2: ii9–14CrossRefGoogle Scholar
  80. 80.
    Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007; 57(7): 1324–8PubMedCrossRefGoogle Scholar
  81. 81.
    Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353(23): 2450–61PubMedCrossRefGoogle Scholar
  82. 82.
    Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12(2): R63PubMedCrossRefGoogle Scholar
  83. 83.
    Schumacher Jr HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59(11): 1540–8PubMedCrossRefGoogle Scholar
  84. 84.
    Zyloprim® (Allopurinol) [package insert]. San Diego (CA): Prometheus Laboratories Inc, 2003Google Scholar
  85. 85.
    Allopurinol: summary of product characteristics. South Ruislip, UK: Milpharm Ltd, 2009Google Scholar
  86. 86.
    Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007; 66(10): 1311–5PubMedCrossRefGoogle Scholar
  87. 87.
    Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58(1): 25–32PubMedCrossRefGoogle Scholar
  88. 88.
    Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31(8): 1575–81PubMedGoogle Scholar
  89. 89.
    Komoriya K, Hoshide S, Takeda K, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004; 23(8–9): 1119–22PubMedCrossRefGoogle Scholar
  90. 90.
    ULORIC® (Febuxostat) [package insert]. North Deerfield (IL): Takeda Pharmaceuticals America, 2009Google Scholar
  91. 91.
    Perez-Ruiz F. Risk factors for renal lithiasis during treatment with uricosuric drugs [abstract]. Arthitis Rheum 2009; 60(10): 1499Google Scholar
  92. 92.
    Schlesinger N, Yasothan U, Kirkpatrick P. Pegloticase. Nat Rev Drug Discov 2011; 10(1): 17–8PubMedCrossRefGoogle Scholar
  93. 93.
    Varela-Echavarria A, Montes de Oca-Luna R, Barrera-Saldana HA. Uricase protein sequences: conserved during vertebrate evolution but absent in humans. Faseb J 1988; 2(15): 3092–6PubMedGoogle Scholar
  94. 94.
    Maroli AN, Waltrip R, Alton M, et al. First application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1111Google Scholar
  95. 95.
    Sundy JS, Baraf HSB, Becker MA, et al. Efficacy and safety of intravenous pegloticase (PGL) in treatment failure gout (TFG): results from GOUT1 and GOUT2 [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 318CrossRefGoogle Scholar
  96. 96.
    Savient Pharmaceuticals Ltd. Krystexxa™ (pegloticase): prescribing information [online]. Available from URL: www.krys texxa.com/pdfs/KRYSTEXXAPrescribin g_Information.pdf [Accessed 2011 Jun 27]Google Scholar
  97. 97.
    Anderson A, Singh JA. Pegloticase for chronic gout. Cochrane Database Syst Rev 2010; 3: CD008335PubMedGoogle Scholar
  98. 98.
    Wright D, Sundy JS, Rosario-Jansen T. Routine serum uric acid (SUA) monitoring predicts antibody-mediated loss of response and infusion reaction risk during pegloticase therapy [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1104Google Scholar
  99. 99.
    So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9(2): R28PubMedCrossRefGoogle Scholar
  100. 100.
    Cho M, Ghosh P, Hans G, et al. The safety and efficacy of Anakinra in the treatment of acute gout in hospitalized patients [abstract]. Arthritis Rheum 2010; 60 Suppl. 9: 163Google Scholar
  101. 101.
    Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, mono-sequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68(10): 1613–7PubMedCrossRefGoogle Scholar
  102. 102.
    Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011; 70(7): 1264–71PubMedCrossRefGoogle Scholar
  103. 103.
    Schumacher RH, Sundy JS, Terkeltaub R, et al. Placebo-controlled study of rilonacept for prevention of gout flares during initiation of urate-lowering therapy [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 680Google Scholar
  104. 104.
    Perez-Ruiz F, Hingorani V, Welp J, et al. Efficacy and safety of a range of doses of RDEA594, a novel uricosuric agent, as a single agent in hyperuricemic gout patients: multicenter, randomized, double-blind, placebo-controlled, phase 2 experience [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3: 121Google Scholar
  105. 105.
    Sundy JS, Kitt M. Tranilast, a novel, potential treatment for the chronic management of hyperuricemia in patients with gout, reduces serum uric acid (SUA) in healthy subjects [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3: 607Google Scholar
  106. 106.
    Fitz-Patrick D, Drummond W, Pappas J, et al. Effects of a purine nucleoside phosphorylase inhibitor, BCX4208, on the serum uric acid concentrations in patients with gout. 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7–11; Atlanta (GA)Google Scholar
  107. 107.
    Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008; 4(1): 34–42PubMedCrossRefGoogle Scholar
  108. 108.
    So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008; 10(5): 221PubMedCrossRefGoogle Scholar
  109. 109.
    Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201(9): 1355–9PubMedCrossRefGoogle Scholar
  110. 110.
    Tunyogi-Csapo M, Kis-Toth K, Radacs M, et al. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum 2008; 58(8): 2397–408PubMedCrossRefGoogle Scholar
  111. 111.
    Kim JH, Jin HM, Kim K, et al. The mechanism of osteoclast differentiation induced by IL-1. J Immunol 2009; 183(3): 1862–70PubMedCrossRefGoogle Scholar
  112. 112.
    Burger D, Dayer JM, Palmer G, et al. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20(5): 879–96PubMedCrossRefGoogle Scholar
  113. 113.
    Kapur S, Bonk ME. Rilonacept (Arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. Pharm Ther 2009; 34(3): 138–41Google Scholar
  114. 114.
    Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10(3): R67PubMedCrossRefGoogle Scholar
  115. 115.
    Terkeltaub R, Sundy JS, Schumacher HR, et al. The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis 2009; 68(10): 1613–7PubMedCrossRefGoogle Scholar
  116. 116.
    Neogi T. IL-1 antagonism in acute gout: is targeting a single cytokine the answer? Arthritis Rheum 2010; 62(10): 2845–9PubMedCrossRefGoogle Scholar
  117. 117.
    Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 2004; 6(3): 240–7PubMedCrossRefGoogle Scholar
  118. 118.
    Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002; 29(9): 1942–9PubMedGoogle Scholar
  119. 119.
    Dalbeth N, So A. Hyperuricaemia and gout: state of the art and future perspectives. Ann Rheum Dis 2010; 69(10): 1738–43PubMedCrossRefGoogle Scholar
  120. 120.
    Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417(6887): 447–52PubMedGoogle Scholar
  121. 121.
    Ardea Biosciences, Inc. Allopurinol combination study (RDEA594-203) [ClinicalTrials.gov identifier NCT01001338]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 27]
  122. 122.
    Mandal A, Emerling D, Serafini T, et al. Tranilast inhibits urate transport mediated by URAT1 and GLUT 9. 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7–11; Atlanta (GA)Google Scholar
  123. 123.
    Serafini TA, Emerling DE. Tranilast suppresses inflammation induced by monosodium urate (MSU) crystals in vivo [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3: 664Google Scholar
  124. 124.
    Nuon Therapeutics, Inc. Tranilast plus allopurinol in patients with moderate to severe gout (TAnGO) [ClinicalTrials.gov identifier NCT01109121]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 27]
  125. 125.
    BioCryst Pharmaceuticals. Study to evaluate sUA-lowering activity, safety and PK interaction of oral BCX4208 and allopurinol administration in subjects with gout [ClinicalTrials.gov identifier NCT01129648]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 27]

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of MedicineUniversity of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations